Hepatocellular carcinoma (HCC) is the fifth most
common tumor worldwide and the incidence of HCC
has been rising over the past few decades in some areas
such as Europe, USA and eastern Asian countries
(Marrero, 2006). Malignant gliomas are one of the more
lethal forms of cancer. An estimated 18,000 new cases of
brain and central nervous system tumors are diagnosed
each year and approximately 13,000 people died of their
disease in the United States alone (American Cancer
Society, 2006). Despite advances in diagnosis and
standard therapies such as surgery, radiation, and
chemotherapy, HCC remains a formidable challenge for
clinical therapy systems